Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial
Biliary tract cancers (BTCs) are a difficult-to-treat group of tumors with an overall poor prognosis. Until 2022, combination chemotherapy was the first-line treatment standard for patients with advanced BTCs, achieving a moderate patient survival improvement. The evolution of chemoimmunotherapy has...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2024.21.157 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!